Novel Targeted Photosensitizer as an Immunomodulator for Highly Efficient Therapy of T-Cell Acute Lymphoblastic...

Area of Science:

• Oncology
• Immunology
• Medicinal Chemistry

Background:

• Dasatinib is a kinase inhibitor for leukemia but faces challenges with drug resistance and side effects.
• Photodynamic therapy (PDT) can elicit systemic immune responses, but current photosensitizers are insufficient for eliminating residual cancer cells.
• Targeting lymphocyte-specific protein tyrosine kinase (LCK) is crucial for treating T-cell acute lymphoblastic leukemia.

Purpose of the Study:

• To synthesize and evaluate a novel compound integrating dasatinib and zinc(II) phthalocyanine for targeted leukemia therapy.
• To assess the compound's affinity for LCK-overexpressing cells and its efficacy in photocytotoxicity and tumor regression.
• To investigate the compound's potential to enhance anti-cancer immune responses.

Main Methods:

• Synthesis of a novel dual-acting compound (Compound 4) combining dasatinib and zinc(II) phthalocyanine.
• In vitro and in vivo evaluation of Compound 4's targeting affinity, photocytotoxicity, and anti-tumor effects.
• Assessment of immune cell production and systemic immune response following Compound 4-mediated PDT.

Main Results:

• Compound 4 demonstrated high affinity for CCRF-CEM cells and LCK-overexpressing tumor tissues.
• The compound exhibited potent photocytotoxicity, leading to significant tumor regression.
• Compound 4-induced PDT markedly enhanced immune responses, increasing immune cell populations.

Conclusions:

• The novel compound offers a targeted approach for leukemia treatment by combining kinase inhibition and photodynamic therapy.
• Compound 4 shows promise as an effective therapeutic strategy for T-cell acute lymphoblastic leukemia by inducing tumor regression and boosting immunity.
• This approach represents a potential advancement in overcoming drug resistance and improving treatment outcomes in leukemia.